Recent Advances in Immunotherapy for Breast Cancer: A Review.
Qian-Er WenLiang LiRui-Qi FengDe-Hui LiChang QiaoXiao-Song XuYan-Jing ZhangPublished in: Breast cancer (Dove Medical Press) (2024)
Breast cancer is one of the most common malignant tumors in women in the world, and its incidence is increasing year by year, which seriously threatens the physical and mental health of women. Triple negative breast cancer (TNBC) is a special molecular type of breast cancer in which estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are negative. Compared with other molecular types of breast cancer, triple-negative breast cancer (TNBC) has high aggressiveness and metastasis, high recurrence rate, lack of effective therapeutic targets, and usually poor clinical treatment effect. Chemotherapy was the main therapeutic means used in the past. With the advent of the immune era, immunotherapy has made a lot of progress in the treatment of triple-negative breast cancer (TNBC), bringing new therapeutic hope for the treatment of triple-negative breast cancer. This review combines the results of cutting-edge medical research, mainly summarizes the research progress of immunotherapy, and summarizes the main treatment methods of triple-negative breast cancer (TNBC) immunotherapy, including immune checkpoint inhibitors, tumor vaccines, adoptive immunotherapy and the application of traditional Chinese and western medicine. It provides a new idea for the treatment of triple negative breast cancer (TNBC).
Keyphrases
- mental health
- epidermal growth factor receptor
- estrogen receptor
- type diabetes
- stem cells
- physical activity
- squamous cell carcinoma
- young adults
- combination therapy
- metabolic syndrome
- risk factors
- polycystic ovary syndrome
- mesenchymal stem cells
- replacement therapy
- advanced non small cell lung cancer
- tyrosine kinase
- breast cancer risk
- mental illness
- binding protein